Christine E Brown, Jonathan C Hibbard, Darya Alizadeh, M Suzette Blanchard, Heini M Natri, Dongrui Wang, Julie R Ostberg, Brenda Aguilar, Jamie R Wagner, Jinny A Paul, Renate Starr, Robyn A Wong, Wuyang Chen, Noah Shulkin, Maryam Aftabizadeh, Aleksandr Filippov, Ammar Chaudhry, Julie A Ressler, Julie Kilpatrick, Paige Myers-McNamara, Mike Chen, Leo D Wang, Russell C Rockne, Joseph Georges, Jana Portnow, Michael E Barish, Massimo D'Apuzzo, Nicholas E Banovich, Stephen J Forman, Behnam Badie
Chimeric antigen receptor T cell (CAR-T) therapy is an emerging strategy to improve treatment outcomes for recurrent high-grade glioma, a cancer that responds poorly to current therapies. Here we report a completed phase I trial evaluating IL-13Rα2-targeted CAR-T cells in 65 patients with recurrent high-grade glioma, the majority being recurrent glioblastoma (rGBM). Primary objectives were safety and feasibility, maximum tolerated dose/maximum feasible dose and a recommended phase 2 dose plan. Secondary objectives included overall survival, disease response, cytokine dynamics and tumor immune contexture biomarkers...
March 7, 2024: Nature Medicine